source
- Outpace Bio halts Phase 1 ovarian cancer CAR‑T trialOutpace Bio announced that it has stopped its Phase 1 trial of OPB-101, an autologous CAR‑T therapy targeting mesothelin in ovarian cancer. The company said the trial will no longer enroll patient…
- Ferring to acquire next-gen IVF startup Gameto for up to $1.4BThe buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization.BioPharma Dive · 21d ago↗ source